GlassScriptPhysician profile
Roshini Devi Singh
NPI 1477952034
$1,542.07
in general payments reported to CMS, 2019-2025
12 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $110 · 2023: $423 · 2024: $313 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.83 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $217.90 | 2025 | Kisunla, Zepbound |
| Horizon Therapeutics Plc | $125.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $124.46 | 2023 | Soliris |
| Genzyme Corporation | $119.81 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $119.81 | 2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.17 | 2021 | |
| Amgen INC. | $109.91 | 2022 | |
| Viatris Specialty LLC | $106.32 | 2025 | Yupelri |
| Alnylam Pharmaceuticals INC. | $101.60 | 2023 | Amvuttra |
| Livanova USA, INC. | $82.68 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Pfizer INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshini Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.